Back to HLUYY
Phase 3
Development Phase
0
Upcoming Catalysts
1
Historical Events
1
Regulatory Approvals
Competitive Landscape
0 competitors in Chronic Migraine in Children
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA1/24/2022
Vyepti
Vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts